130250-07-6

Upstream product

• 6698-46-0 5-O-benzoyl-1,2-O-isopropylidene-α-D-ribofuranos-3-ulose 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 6022-96-4 5-O-benzoyl-α-D-xylofuranose 
• 98-88-4 benzoyl chloride 
• 149207-10-3 (3aR,5S,6R,6aR)-6-Benzyloxymethyl-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxole-5-carbaldehyde 
• 69832-48-0 3-C-deoxy-3-C-hydroxymethyl-1,2;5,6-di-O-isopropylidene-α-D-allo-furanose 
• 100-39-0 benzyl bromide 
• 604801-31-2 3-C-(benzyloxymethyl)-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 
• 130250-06-5 5-O-benzoyl-1,2-O-isopropylidene-3-C-<(benzyloxy)methylene>-α-D-ribofuranose 

Downstream Products

• 130250-08-7 5-O-benzoyl-3-deoxy-3-<(benzyloxy)methyl>-α,β-D-ribofuranose 
• 175876-70-7 (3R,4S,5R)-5-<(benzoyloxy)methyl>-4-<(benzyloxy)methyl>tetrahydrofuran-3-ol 
• 175876-71-8 (3R,4S,5R)-5-<(benzoyloxy)methyl>-4-<<(TBDMS)oxy>methyl>-tetrahydrofuran-3-ol 
• 175876-72-9 (2S,3S,4R)-2-<(benzoyloxy)methyl>-3-<<(TBDMS)oxy>methyl>-4-<(methylsulfonyl)oxy>tetrahydrofuran 
• 175876-73-0 Benzoic acid (2S,3R,4S)-4-(6-amino-purin-9-yl)-3-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-2-ylmethyl ester 
• 175876-75-2 N'-{9-[(3S,4R,5S)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-3-yl]-9H-purin-6-yl}-N,N-dimethyl-formamidine 
• 142820-81-3 methyl 5-O-benzoyl-3-C-(benzyloxymethyl)-3-deoxy-β-D-ribofuranoside 
• 130250-09-8 9-<3'-deoxy-3'-<(benzyloxy)methyl>-2,5-di-O-benzoyl-β-D-ribofuranosyl>-6-chloropurine 
• 130250-05-4 1,2,5-tri-O-benzoyl-3-deoxy-3-<(benzyloxy)methyl>-α,β-D-ribofuranose 
• 26289-43-0 6-amino-9-<3-deoxy-3-(hydroxymethyl)-β-D-ribofuranosyl>-9H-purine 

Relevant academic research and scientific papers

Synthesis of 3′-acetamidoadenosine derivatives as potential A 3 adenosine receptor agonists

On the basis of high binding affinity of 3′-aminoadenosine derivatives 2b at the human A3 adenosine receptor (AR), 3′- acetamidoadenosine derivatives 3a-e were synthesized from 1,2:5,6-di-O- isopropylidene-D-glucose via stereoselective hydroboration as a key step. Although all synthesized compounds were totally devoid of binding affinity at the human A3AR, our results revealed that 3′-position of adenosine can only be tolerated with small size of a hydrogen bonding donor like hydroxyl or amino group in the binding site of human A3AR. Copyright Taylor & Francis Group, LLC.

Nucleosides and nucleotides. 147. Synthesis of DNA dodecamers containing oxetanocin A and (2R, 3R)-2-C-(adenin-9-yl)-1,4-anhydro-2,3-dideoxy-3-C-hydroxymethyl-D-arabitol

Oxetanocin A (1) and (2R,3R)-2-C-(adenin-9-yl)-1,4-anhydro-2,3-dideoxy-3-C-hydroxy-methyl-D-arabitol (2), a ring-expanded oxetanocin analogue, were incorporated into DNA dodecamers, 5′-d(CGCG1ATTCGCG)-3′ (II), 5′-d(CGCGA1TTCGCG)-3′ (III), 5′-d(CGCG2ATTCGCG)-3′ (IV), and 5′-d(CGCGA2TTCGCG)-3′ (V). Thermally induced transitions of II, III, IV, and V together with a parent dodecamer, 5-d(CGCGAATTCGCG)-3′ (I) were monitored at 260 nm in a buffer containing 0.01 M sodium phosphate (pH 7.0), 0.02 M NaCl, and 6 μM of each dodecamer. The order of Tms was 40 °C (I) > 37 °C (IV) > 36 °C (V) > 34 °C (II) > 32 °C (III). The oligonucleotide containing 2 was more resistant to snake venom phosphodiesterase than unmodified DNA dodecamer (I).

A NEW AND NOVEL APPROACH TOWARDS THE SYNTHESIS OF 3'-DEOXY-3'-HYDROXYMETHYL RIBOFURANOSIDES

The synthesis of 1,2,5-tri-O-benzoyl-3-deoxy-3--α,β-D-ribofuranose (1) from 1,2-O-isopropylidene-α-D-xylofuranose (2) has been achieved in an overall yield of 37percent.Compound 1 is a properly substituted intermediate for the synthesis